17:02 EST Ocuphire Pharma files $175M mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OCUP:
- Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
- Ocuphire Pharma receives FDA agreement under SPA for LYNX-2 Phase 3 trial
- Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
- Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ocuphire Pharma announces appointment of Schachle as COO